

02/08/02

Please type a plus (+) inside this box -



PTO/SB/29 (12/97)

Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

7853-233-999

Total Pages

159

First Named Inventor or Application Identifier

Katherine GALVIN et al.

Express Mail Label No.

N/A

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

Assistant Commissioner for Patents

ADDRESS TO: Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form
Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages 127]
(preferred arrangement set forth below)

-Descriptive title of the Invention
-Cross Reference to Related Applications
-Statement Regarding Fed sponsored R&D
-Reference to Microfiche Appendix
-Background of the Invention
-Brief Summary of the Invention
-Brief Description of the Drawings (if filed)
-Detailed Description of the Invention (including drawings, if filed)
-Claim(s)
-Abstract of the Disclosure

3. ☒ Drawing(s) (35 USC 113) [Total Sheets 26]

4. ☒ Oath or Declaration [Total Sheets 6]

- a. ☐ Newly executed (original or copy)
b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]

- i. ☐ DELETION OF INVENTORS(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).

5. ☒ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. ☒ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- a. ☐ Computer Readable Copy
- b. ☒ Paper Copy (identical to computer copy)
- c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☒ Assignment Papers (copy of Notice of Recordation, cover sheet & documents from parent application)
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 Citations
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Applicant claims Small Entity status, see 37 C.F.R. § 1.27
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Other:

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)

of prior application No: 09/288,292 filed April 8, 1999, which is a continuation-in-part of

Application Serial No. 08/870,434, filed June 6, 1997, which is a continuation-in-part of co-pending Application Serial No. 08/799,910, filed February 13, 1997, which claims priority benefit under 35 U.S.C. §119(e) of provisional Application Serial No. 60/011,787, filed February 16, 1996; and this application is a continuation-in-part of Application Serial No. 08/485,573, filed June 7, 1995, which is a continuation-in-part of co-pending Application Serial No. 08/386,844, filed February 10, 1995.

18. CORRESPONDENCE ADDRESS

Customer Number:



20582

(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

NAME

ADDRESS

CITY

STATE

ZIP CODE

COUNTRY

TELEPHONE

FAX

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Prior application: Examiner P. Paras, Jr.Art Unit 1632Assistant Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

This is a request for filing a ☒ continuation ☐ divisional application under 37 CFR § 1.53(b), of pending prior application no. 09/288,292 filed on April 8, 1999.

of Katherine GALVIN, Dean A. FALB, Michael J. DONOVAN, Dennis HUSZAR, Michael A. GIMBRONE, Jr.

(inventor(s) currently of record in prior application)

for COMPOSITIONS AND METHODS FOR TREATMENT AND DIAGNOSIS OF CARDIOVASCULAR DISEASE

(title of invention)

1. ☒ The filing fee is calculated below:

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	16	-20	0	\$18.00 each	\$ 0.00
Independent	3	-3	0	\$84.00 each	\$ 0.00
Basic Fee					\$ 740.00
Multiple Dependency Fee If Applicable (\$280.00)					\$ 0.00
Total					\$ 740.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern					- \$ 0.00
Total Filing Fee					\$ 740.00


2. ☒ Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.
3. ☐ Amend the specification by inserting before the first line the following sentence: This is a continuation, division, of application no. , filed .

- 2006741-020002
- 4a. ☒ New formal drawings are enclosed.
 - 4b. ☐ Informal drawings are enclosed.
 - 5a. ☐ Priority of application no. filed on in is claimed under 35 U.S.C. §119.
 - 5b. ☐ The certified copy has been filed in prior application no. , filed .
 - 6. ☒ The prior application is assigned of record to Millennium Pharmaceuticals, Inc. of Cambridge, Massachusetts and Brigham and Women's Hospital of Boston, Massachusetts as recorded at Reel 010221, Frame 0754 on September 9, 1999, a copy of which is attached.
 - 7a. ☒ A copy of the Declaration and Power of Attorney filed in the prior application no. 09/288,292, filed April 8, 1999 is enclosed.
 - 7b. ☐ A Power of Attorney is enclosed.
 - 8. ☒ This application contains nucleic acid and/or amino acid sequences required to be disclosed in a Sequence Listing under 37 CFR §§1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior application no.09/288,292, filed on September 9, 1999 be made a part of the present application as provided for by 37 C.F.R. §1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from application no. 09/288,292 is enclosed.
 - 9. ☒ The undersigned states, under 37 C.F.R. §1.821(f), that the content of the enclosed paper Sequence Listing from application no. 09/288,292 is the same as the content of the computer readable form submitted in application no. 09/288,292.
 - 10. ☐ DO NOT PUBLISH. I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

11. ☒ Additional enclosures or instructions.
Preliminary Amendment
Copy of parent application
Information Disclosure Statement and PTO Form-1449

Respectfully submitted,

Date February 8, 2002

 39,445
Serge Sira (Reg. No.)
PENNIE & EDMONDS LLP
1667 K Street, N.W.
Washington, D.C. 20006

For: Laura A. Coruzzi, Reg. No. 30,742

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
Phone: (212) 790-9090

Enclosures

1006741.02002
20020208